Ensifentrine

恩司芬群

Report date: 2026/05/14 20:00:28
NME

Base Information

Drug NameEnsifentrine
Drug Alias Name恩塞芬汀OhtuvayreRPL-554VMX-554VRP-554
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionPhosphodiesterase 3 inhibitorsPhosphodieterase 4 inhibitors
TargetsPhosphodiesterase 3Phosphodieterase 4
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)InflammationPulmonary Disease, Chronic Obstructive +[6] 
Global Approved IndicationsPulmonary Disease, Chronic Obstructive
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date2024/06/26
Country/TerritoryCzechiaBelgiumBulgaria +[19] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesVernalis Plc
China Registration ClassN/A

Develop Information

Active CompaniesVerona PharmaYurui Pharmaceutical Technology (Shanghai) Co LtdNuance Pharma Ltd +[4] 
Inactive CompaniesVerona Pharma IncUniversity Of Alabama At Birmingham
Active IndicationsPulmonary Disease, Chronic Obstructive
Inactive IndicationsCoronavirus Disease 2019 (COVID-19)InflammationAsthma +[5] 

Other Information

ATC CodeN/A
Related LinksWikipediaDrugBankKEGG